2,3 Here, we describe the first SME-positive isolates identified by PHE since screening for carbapenemases began in the early 2000s.
Sir, Serratia marcescens enzymes (SMEs) are class A carbapenemases found on the chromosome of S. marcescens. First identified in the UK in 1982, 1 SME carbapenemases have since been identified most often in the USA, Canada and Argentina, with a single isolate from Switzerland. 2, 3 Here, we describe the first SME-positive isolates identified by PHE since screening for carbapenemases began in the early 2000s.
The seven S. marcescens isolates were from three patients and were submitted to PHE's Antimicrobial Resistance and Healthcare Associated Infections (AMRHAI) Reference Unit for investigation of carbapenem resistance. Isolates 1-3 were recovered from a GP patient in south-east England, isolate 4 was from an inpatient in north-west England and isolates 5-7 were from an inpatient in London (see Table 1 ). None of the patients had a history of recent travel abroad. Both inpatients had been admitted to other hospitals in the weeks preceding isolation of the S. marcescens, but no similar S. marcescens isolates have been submitted to AMRHAI by these hospitals.
MICs were determined against AMRHAI's standard panel of Gram-negative antibiotics, using agar dilution and interpreted using EUCAST criteria. Isolates 1, 4 and 5 (one isolate per patient) were screened for carbapenemase activity using the RAPIDEC V R CARBANP test (bioMérieux) and the Carbapenemase Inactivation Method (CIM). 4 Isolate 4 was positive in the modified Hodge test based on local laboratory testing. Carbapenemase genes, including bla SME , were sought using in-house PCRs. WGS was performed on isolates 1, 4 and 5 using a Hiseq sequencer (Illumina) and the resulting data analysed as previously described. 5 Typing was performed by PFGE of XbaI-digested genomic DNA.
Isolates showed resistance to imipenem (MICs .128 mg/L), meropenem (MICs 16 mg/L) and ertapenem (MICs 8 mg/L), but were relatively susceptible to the third-generation cephalosporins (see Table 1 ); these profiles were suggestive of class A carbapenemase production. bla SME genes were detected in all seven isolates by PCR, and were subsequently identified via WGS as bla SME-4 in isolates 1 and 5, and bla SME-2 in isolate 4. The only other resistance gene detected by WGS was aac(6 0 )-Ic, which is chromosomally located in all S. marcescens, but may not be expressed. 6, 7 Isolates 1, 4 and 5 had unique PFGE patterns.
Short-read WGS data were mapped against SME-associated S. marcescens genomic island SmarGI1-1 sequences. 3 This revealed that the SmarGI1-1 and flanking regions of isolate 1 were identical to GenBank accession number KF615855, in isolate 4 differ from KF445086 by 8 SNPs and in isolate 5 differ from KF615855 by 53 SNPs, indicating that bla SME genes in the UK are found in the V C Crown copyright 2017.
same genetic environment as previously reported in S. marcescens in Canada with only minor sequence differences. Mobilization of bla SME has been proposed via an excised circular intermediate of SmarGI1-1, 3 and the distinct PFGE patterns of our isolates support horizontal transfer of this island. It would appear that the circular intermediate can only transfer between S. marcescens strains as bla SME genes have not yet been identified outside of this species.
Carbapenemase-producing S. marcescens account for only 45 isolates amongst .7800 CPE confirmed by AMRHAI since screening began in the early 2000s (19 with an OXA-48-like enzyme, 10 KPC, 7 NDM, 7 SME, and 1 each of GES-5 and VIM; K. L. Hopkins and N. Woodford, AMRHAI, unpublished data). Identification of SME carbapenemases in genetically unrelated S. marcescens isolates from three patients with no known epidemiological links suggests that these carbapenemases are circulating in the UK, albeit at a low level.
Organisms harbouring chromosomally located carbapenemases could be considered slightly less of an infection control risk compared with other CPE where plasmid-mediated transmission of the carbapenemase is possible, but prompt recognition is necessary to prevent an outbreak due to clonal dissemination. However, phenotypic detection of SME carbapenemases can be problematic. SMEproducers have only weak hydrolytic activity towards the thirdgeneration cephalosporins, often remaining susceptible or intermediate unless, as here, chromosomal AmpC activity is derepressed. Susceptibility to ertapenem and meropenem (but not imipenem) has been reported in some isolates, though ours were all clearly resistant to all three carbapenems. 3, 8 The modified Hodge test and some variations of the CARBANP assay are reportedly unreliable for detection of SME-mediated carbapenemase activity, 3,9,10 although we detected activity with both RAPIDEC V R CARBANP and CIM assays in representatives of all three strains.
bla SME genes are currently not detected by any commercial molecular assays although, based on increasing isolations of SMEpositive S. marcescens in North America, a recommendation for inclusion of this gene family into future PCR and microarray assays has been made. 2 Diagnostic laboratories should be alert to the presence of SME-producing S. marcescens in the UK and have a high index of suspicion for isolates with a meropenem MIC above the EUCAST screening concentration for meropenem (i.e. .0.125 mg/ L), with or without full resistance to imipenem (MICs .8 mg/L, though MICs for most SME producers are .128 mg/L) as opposed to reduced susceptibility or intermediate resistance, which is intrinsic to the species. Isolates suspected of SME production should be referred to AMRHAI for further characterization.
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